8月29日,江苏联环药业股份有限公司(以下简称“联环药业”)发布2026年半年度报告。报告期内,公司实现营业收入15.71亿元,同比增长22.21%;归属于上市公司股东的净利润为1052.18万元,同比扭亏为盈。 在医药行业持续推进结构调整的背景下,联环药业经营业绩实现改善。与此同时,公司多个集采品种中标续采并持续推进市场上量,重点创新药LH-1801完成临床试验揭盲并提交Pre-NDA沟通交流...
Source Link8月29日,江苏联环药业股份有限公司(以下简称“联环药业”)发布2026年半年度报告。报告期内,公司实现营业收入15.71亿元,同比增长22.21%;归属于上市公司股东的净利润为1052.18万元,同比扭亏为盈。 在医药行业持续推进结构调整的背景下,联环药业经营业绩实现改善。与此同时,公司多个集采品种中标续采并持续推进市场上量,重点创新药LH-1801完成临床试验揭盲并提交Pre-NDA沟通交流...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.